영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - colestyramine anhydrous - powder for oral suspension - 4gram

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - colestyramine anhydrous - powder for oral suspension - 4gram

사우디아라비아 - 영어 - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

meadjohnson, united states - colestyramine - powder - 4 g

일본 - 영어 - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - colestyramine - faint orangish white powder

일본 - 영어 - すりの適正使用協議会 RAD-AR Council, Japan

sanofi k.k. - colestyramine - faint orangish white powder

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; purified talc; magnesium stearate; aluminium magnesium silicate; povidone - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; aluminium magnesium silicate; purified talc - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; croscarmellose sodium; povidone; purified talc; aluminium magnesium silicate; magnesium stearate; microcrystalline cellulose - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate